- Global Wellness Strategies (GWS) has formed a wholly-owned pharma subsidiary focused on clinical trials
- Global Wellness acquired Shanti Therapeutics in 2022, and iNGENü is engaged as the clinical research organization by the company to conduct clinical trials for Shanti
- Canada-based PharmAla Biotech is to supply MDMA for Shanti Therapeutics’ upcoming clinical trial and will disclose receipt of MDMA shortly as the company readies for its import permit to Australia
- Global Wellness Strategies (GWS) is unchanged, trading at $0.30 per share as of 10:45 a.m. ET
Global Wellness Strategies (GWS) has formed a wholly-owned pharma subsidiary focused on clinical trials.
Global Wellness acquired Shanti Therapeutics in 2022, and all share issuances for the acquisition have been completed. iNGENü, a subsidiary of Australian leader Cannvalate, is engaged as the clinical research organization by the company to conduct clinical trials for Shanti Therapeutics.
Canada-based PharmAla Biotech is to supply MDMA for Shanti Therapeutics’ upcoming clinical trial and will disclose receipt of MDMA shortly as the company readies for its import permit to Australia.
The protocol is a randomized crossover study to investigate the efficacy of MDMA vs placebo in a model of experimental pain in healthy adults. Shanti has a targeted research pathway to clinical success, with strong proprietary protection under its already submitted patent providing a method for the treatment or prevention of pain.
Meris Kott, CEO of Global Wellness Strategies, commented that real strategic capital market partnerships are essential to assist the company’s clients in their progression to the next level with their organic growth.
“Forming a pharma subsidiary focused primarily on funding clinical trials is essential to our partners’ successes.”
Global Wellness Strategies Inc. (GWS) is a debt financing company. The company provides a debt financing facility to help companies build their valuation and get to the next level in its financing cycle without giving away equity prematurely in their growth cycle. It is focusing on providing finance to medical cannabis, hemp, and CBD-related, healthcare-related target companies.
Global Wellness Strategies (GWS) is unchanged, trading at $0.30 per share as of 10:45 a.m. ET.